Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Terns Pharmaceuticals
Company

Terns Pharmaceuticals

Tracked across 2 events · 12 articles · First seen Jun 15, 2026 · Last active Aug 04, 2026

Sentiment
-10
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 -20
Business
Merck beats Q2 on Keytruda strength
Merck reported second-quarter revenue of $16.61 billion, up 5% year-over-year and above analyst expectations, driven by strong sales of its cancer drug Pembrolizumab. Pembrolizumab sales rose 5% to $8.37 billion, including $463 million from the…
Impact: Terns was acquired by Merck, resulting in a $5.7 billion charge that caused a quarterly loss. The acquisition is part of Merck's pipeline expansion.
Aug 04, 2026 · 6 articles
4 0
Business
Immuneering Appoints Andrew Gengos CFO
Impact: Andrew Gengos previously served as Chief Financial Officer and Head of Corporate Development at Terns Pharmaceuticals.
Jun 15, 2026 · 6 articles
Key Actions (1)
60 Merck Group acquired Terns Pharmaceuticals Terns PharmaceuticalsMerck beats Q2 on Keytruda strength
ERGEN INTELLIGENCE
Track Terns Pharmaceuticals live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.